Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market
Pfizer and Roche Also In The Running
Executive Summary
Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.
You may also be interested in...
Could Prevention Data Give REGEN-COV Competitive Leg Up?
Could Prevention Data Give REGEN-COV Competitive Leg Up?
Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir
Pfizer reported its protease inhibitor Paxlovid showed an 89% risk reduction for hospitalization and death compared to placebo in interim results of a Phase II/III trial. The pharma now is seeking a quick EUA in the US.
Merck Forecasts Global Molnupiravir Revenues Of $5bn-$7bn Through 2022
Assuming emergency use authorization of the antiviral to fight COVID-19 in December, Merck expects to make $500m-$1bn this year. It will share profits equally with partner Ridgeback.